PUBLISHED DATE : Mar 2023 | Pages : 165
Fill out your details & get your free sample
The U.S. Monkeypox Testing Market Size, Share, & Trends Analysis Report By
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023–2025
165 Pages
55 Tables
56 Charts
4 Regions
1 Countries
36 Companies
3 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2025) | USD 91.00 Thousand |
| Market Size (2022) | USD 5,336.29 Thousand |
| CAGR (2022-2025) | (74.26%) |
| Base Year | 2022 |
| Forecast Year | 2023-2025 |
| Market Segments | Type, End-User, and Geography |
| REGIONAL ANALYSIS | U.S. (Southern, Western, Northeast, and Central) |
| KEY VENDORS | Abbott, F. Hoffmann-La Roche, Qiagen, and Thermo Fisher Scientific |
The U.S. monkeypox testing market size was valued at USD 5,336.29 thousand in 2022 and is expected to reach USD 91 thousand by 2025. The market is projected to register a CAGR of (74.26%) during the forecast period. Monkeypox is an orthopoxviral related to the smallpox virus and initially affected the U.S. population in 2003. Cases of monkeypox increased at the beginning of 2022, and by the end of September, the U.S. became the country with a high number of monkeypox cases. Men accounted for the larger patient group in the country; however, the number of monkeypox cases among women and children was limited.
The major reason for the spread of the disease in the country was sex among men. The LGBT community was one of the majorly affected communities. The country has undergone a huge healthcare crisis due to COVID-19 cases and has taken significant steps to control the spread of infections in the market. The region increased the number of tests conducted and accessibility to the tests through various healthcare settings, thereby contributing to the U.S. monkeypox testing market. Such initiatives have helped the country manage the spread of the disease.
The COVID-19 pandemic made the U.S. healthcare system increase its testing capacity and handle outbreaks and pandemics better. The monkeypox virus was diagnosed through the PCR-based method, like the COVID-19 infection testing, and has helped the government immediately increase the testing and provide treatment to the infected people and contribute to the U.S. monkeypox testing market. From day one of this outbreak, providers had access to a high-quality, FDA-cleared test to detect monkeypox. The CDC has scaled the testing capacity to 78 sites in 48 states, primarily at state public health laboratories, with the capacity to conduct around 10,000 tests per week. In addition, CDC began shipping the tests to some of the largest commercial laboratory companies (including some of the nation’s largest reference laboratories) to increase monkeypox testing capacity. This action improved convenience for patients and healthcare providers across the nation, and the government eased the testing procedures by approving the rapid testing kits for monkeypox. The regulatory bodies approved the products faster and increased access to monkeypox testing, which further accelerated the U.S. monkeypox testing market. In addition, the government took better steps to create awareness, communicate among the LGBTQI+ community, mobilize them, and provide better treatments. It was estimated that the U.S. would require USD 7 billion to handle the monkeypox outbreak.
This expansion increased the testing accessibility, building on the capacities already available within the Laboratory Response Network (LRN). In addition, the CDC has worked with the LRN to increase public health testing capacity by more than 50% since the outbreak's start, increasing testing capacity from 6,000 tests per week to approximately 10,000 tests per week. This network continued to provide spare testing capacity to jurisdictions across the country. CDC worked with the state, territorial, and local health departments to make the monkeypox testing process more accessible to health care providers.
Monkeypox testing has become very significant in the high-risk community. Monkeypox lesions are extremely painful and curable, but the effect of monkeypox among undiagnosed HIV patients is extreme. This is increasing the number of tests conducted in the country. People with simpler symptoms also undergo monkeypox testing to protect them from other disease conditions. In addition, some factors have limited the Mpox testing. Factors like false positive results and the rollout of vaccines in the market reduced the spread of the infections. Such factors helped the government quickly monitor and reduce the country's monkeypox cases. However, this reduced the number of tests conducted in the market, which became a limitation for the U.S. monkeypox testing market.
Monkeypox Cases Are Down but Not Gone
Experts in infectious disease have made statements like monkeypox cases will never leave the country. The number of cases recorded in the U.S. was high but still considered an undercount. It is expected that more cases are not considered as the physicians have not seen this before. The virus will remain infectious for around three weeks. It is challenging for people to stay isolated for three weeks. There is a high chance that this infection will spread to the animal carriers like rodents and again jump back, reinfecting the human population. There are high chances of increasing the infection spread unless the vaccination process is complete. Developed Countries like the U.S. will largely invest in the testing infrastructure to reduce the spread of the disease in the country. Investment measures further support the growth of the U.S. monkeypox testing market. The “Panic buying” concept will hugely impact the industry, increasing the demand for Mpox testing.
Strong Future Diagnostic Pipeline
The U.S. has a strong pipeline in the monkeypox diagnostic segment. National Institutes of Health (NIH), National Institute of Biomedical Imaging and Bioengineering (NIBIB), Department of Defense (DOD), and more institutions have invested in advanced monkeypox diagnostics. The research results are to be released in the first half of 2023. The country is investing in the future-ready diagnostics segment, which will help the region defend against future cases.
Ongoing U.S. Monkeypox Research Activities
Government departments and agencies, with international allies and partners, are accelerating efforts to undertake critical monkeypox research questions to inform the outbreak response and strategically planning to launch further research. Insights from this research will guide swift action during a public health emergency. These studies are poised to yield insights that will accelerate efforts to combat monkeypox, but more research is needed to fill the priority gaps. The Monkeypox Research Priority Team, led by the White House Office of Science and Technology Policy (OSTP) and including experts across the US government, is developing science and research programs to accelerate the monkeypox outbreak response in the country. Such factors are anticipated to support the U.S. monkeypox testing market growth.
Rapidly Growing Commercial Laboratory-Developed Monkeypox Testing
On 22 June 2022, the U.S. Department of Health and Human Services (HHS) announced the authorization of commercial laboratories to conduct monkeypox tests to expand testing as the U.S. confronts a monkeypox outbreak dramatically, thereby propelling the U.S. monkeypox testing market. The Centers for Disease Control and Prevention (CDC) shipped test kits to commercial laboratory companies, allowing health providers to order tests from the labs directly. These commercial laboratories dramatically expanded testing capacity nationwide and made testing more convenient and accessible for patients and healthcare providers. In addition to the FDA-approved or EUA-approved monkeypox tests (MPOX), certain laboratory-developed tests (LDTs) are also being used to detect monkeypox that has not been reviewed or approved by the FDA. LDT is a type of in vitro diagnostic test designed, manufactured, and used in a CLIA-accredited laboratory at a single site that meets the requirements of a highly complex test.
The Southern region accounted for the largest U.S. monkeypox testing market share at 33.58%. The perception that the response to the monkeypox virus in the South has lacked coordination has rekindled familiar concerns about recent state policies. States like California have followed the CDC's recommendation to prioritize gay and bisexual men in outreach, vaccination, and treatment for monkeypox. Such states have declared a public health emergency and initiated aggressive, targeted vaccination campaigns. Although California has the highest number of cases, Florida, Georgia, and Texas are home to robust gay communities and have just over a quarter of the country’s confirmed monkeypox cases.
Amid the CDC’s orthopoxvirus test expansion, several diagnostics companies are developing and launching their monkeypox-specific assays. BD, Cepheid, and Roche have joined the race to roll out accurate, PCR-quality tests for the disease. BD has joined forces with CerTest to adapt one of the Spanish company’s existing tests to run on the BD Max automated PCR system. At the same time, Cepheid partnered with reagent maker BioGX to design a molecular assay of its own. Abbott is developing a polymerase chain reaction (PCR) test to detect the presence of monkeypox. The company is focused on developing a monkeypox test, which could help the world in the early detection of the disease. It will provide test kits to partners in the pandemic defense coalition. In addition, F. Hoffman La Roche launches LightMix Modular Virus test kits to analyze samples using quantitative PCR technology. Various companies across the globe are developing monkeypox test kits to increase the testing and to decrease the spread of infection globally.
Frequently Asked Questions
How big is the U.S. monkeypox testing market?
The U.S. monkeypox testing market was valued at USD 5,336.29 thousand in 2022 and is expected to reach USD 91 thousand by 2025.
What is the projected CAGR of the U.S. monkeypox testing market during the forecast period?
The U.S. monkeypox testing market is expected to decline at a CAGR of (74.26%) during the forecast period.
Which are the key players in the U.S. monkeypox testing market?
Abbott, F. Hoffmann-La Roche, Qiagen, and Thermo Fisher Scientific are the key companies in the U.S. monkeypox testing market.
Which region holds the largest U.S. monkeypox testing market share?
The southern region dominates the U.S. monkeypox testing market, with a share of 33.58% in 2022.
What are the growing trends in the U.S. monkeypox testing market?
The growing trends in the U.S. monkeypox testing market are ongoing research activities, the rapid development of rapid testing methods, and rapidly growing commercial laboratory-developed monkeypox testing.
The U.S. monkeypox testing market was valued at USD 5,336.29 thousand in 2022 and is expected to reach USD 91.00 thousand by 2025.
The following factors are likely to contribute to the growth of the U.S. monkeypox testing market during the forecast period:
Base Year: 2022
Forecast Year: 2023-2025
The report considers the present scenario of the U.S. monkeypox testing market and its market dynamics for 2023−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.
Key Company Profiles
Other Prominent Vendors
Laboratory-Developed Monkeypox Tests
Segmentation By Type
Segmentation By End-User
Segmentation By Region
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY TYPE
4.3.2 MARKET SEGMENTATION BY END-USER
4.3.3 MARKET SEGMENTATION BY REGION
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 PREMIUM INSIGHTS
6.1 OVERVIEW
7 MARKET AT A GLANCE
8 INTRODUCTION
8.1 OVERVIEW
9 MARKET OPPORTUNITIES & TRENDS
9.1 ONGOING US MONKEYPOX RESEARCH ACTIVITIES
9.2 GROWING DEVELOPMENT OF RAPID TESTING METHODS
9.3 RAPIDLY GROWING COMMERCIAL LABORATORY-DEVELOPED MONKEYPOX TESTING
10 MARKET GROWTH ENABLERS
10.1 INCREASING PRODUCT LAUNCHES
10.2 ADVANCES IN PCR TECHNOLOGY
10.3 MONKEYPOX ERADICATION UNLIKELY TO CONTINUE IN US
11 MARKET RESTRAINTS
11.1 GROWING ACCESS TO VACCINATION AGAINST MONKEYPOX
11.2 MONKEYPOX CASES ARE IN A SHARP DECLINE
11.3 POTENTIAL RISK OF FALSE MONKEYPOX TEST RESULTS
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.1.1 INSIGHTS BY TYPE
12.1.2 INSIGHTS BY END-USER
12.1.3 INSIGHTS BY REGION
12.2 FIVE FORCES ANALYSIS
12.2.1 THREAT OF NEW ENTRANTS
12.2.2 BARGAINING POWER OF SUPPLIERS
12.2.3 BARGAINING POWER OF BUYERS
12.2.4 THREAT OF SUBSTITUTES
12.2.5 COMPETITIVE RIVALRY
13 TESTING TYPE
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 POLYMERASE CHAIN REACTION (PCR)
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.4 LATERAL FLOW ASSAY
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.5 OTHER
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
14 END-USER
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 LABORATORIES
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.4 HOSPITALS & CLINICS
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.5 OTHERS
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
15 REGION
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 SOUTHERN
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.4 WESTERN
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.5 NORTHEAST
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.6 CENTRAL
15.6.1 MARKET OVERVIEW
15.6.2 MARKET SIZE & FORECAST
16 COMPETITIVE LANDSCAPE
16.1 COMPETITION OVERVIEW
16.2 MARKET SHARE ANALYSIS
16.2.1 ABBOTT
16.2.2 F. HOFFMANN-LA ROCHE
16.2.3 QIAGEN
16.2.4 THERMO FISHER SCIENTIFIC
17 KEY COMPANY PROFILES
17.1 ABBOTT
17.1.1 BUSINESS OVERVIEW
17.1.2 PRODUCT OFFERINGS
17.1.3 KEY STRATEGIES
17.1.4 KEY STRENGTHS
17.1.5 KEY OPPORTUNITIES
17.2 F. HOFFMANN-LA ROCHE
17.2.1 BUSINESS OVERVIEW
17.2.2 PRODUCT OFFERINGS
17.2.3 KEY STRATEGIES
17.2.4 KEY STRENGTHS
17.2.5 KEY OPPORTUNITIES
17.3 QIAGEN
17.3.1 BUSINESS OVERVIEW
17.3.2 PRODUCT OFFERINGS
17.3.3 KEY STRATEGIES
17.3.4 KEY STRENGTHS
17.3.5 KEY OPPORTUNITIES
17.4 THERMO FISHER SCIENTIFIC
17.4.1 BUSINESS OVERVIEW
17.4.2 PRODUCT OFFERINGS
17.4.3 KEY STRATEGIES
17.4.4 KEY STRENGTHS
17.4.5 KEY OPPORTUNITIES
18 OTHER PROMINENT VENDORS
18.1 ALPHA DIAGNOSTIC
18.1.1 BUSINESS OVERVIEW
18.1.2 PRODUCT OFFERINGS
18.2 ATILABIOSYSTEMS
18.2.1 BUSINESS OVERVIEW
18.2.2 PRODUCT OFFERINGS
18.3 APPLIED DNA SCIENCES
18.3.1 BUSINESS OVERVIEW
18.3.2 PRODUCT OFFERINGS
18.4 BIOGX
18.4.1 BUSINESS OVERVIEW
18.4.2 PRODUCT OFFERINGS
18.5 BIONEER
18.5.1 BUSINESS OVERVIEW
18.5.2 PRODUCT OFFERINGS
18.6 CERTEST BIOTEC
18.6.1 BUSINESS OVERVIEW
18.6.2 PRODUCT OFFERINGS
18.7 CO-DIAGNOSTICS
18.7.1 BUSINESS OVERVIEW
18.7.2 PRODUCT OFFERINGS
18.8 CORDX
18.8.1 BUSINESS OVERVIEW
18.8.2 PRODUCT OFFERINGS
18.9 CREATIVE BIOGENE
18.9.1 BUSINESS OVERVIEW
18.9.2 PRODUCT OFFERINGS
18.10 ELABSCIENCE BIOTECHNOLOGY
18.10.1 BUSINESS OVERVIEW
18.10.2 PRODUCT OFFERINGS
18.11 LABNOVATION TECHNOLOGIES
18.11.1 BUSINESS OVERVIEW
18.11.2 PRODUCT OFFERINGS
18.12 SEEGENE
18.12.1 BUSINESS OVERVIEW
18.12.2 PRODUCT OFFERINGS
19 LABORATORY-DEVELOPED MONKEYPOX TESTS
19.1 AEGIS SCIENCES
19.1.1 BUSINESS OVERVIEW
19.1.2 PRODUCT OFFERINGS
19.2 ARUP LABORATORIES
19.2.1 BUSINESS OVERVIEW
19.2.2 PRODUCT OFFERINGS
19.3 APOSTLE DIAGNOSTICS
19.3.1 BUSINESS OVERVIEW
19.3.2 PRODUCT OFFERINGS
19.4 CALIFORNIA DEPARTMENT OF PUBLIC HEALTH
19.4.1 BUSINESS OVERVIEW
19.4.2 PRODUCT OFFERINGS
19.5 CDR COMPANIES
19.5.1 BUSINESS OVERVIEW
19.5.2 PRODUCT OFFERINGS
19.6 CIRRUSDX
19.6.1 BUSINESS OVERVIEW
19.6.2 PRODUCT OFFERINGS
19.7 CLINICAL REFERENCE LABORATORY
19.7.1 BUSINESS OVERVIEW
19.7.2 PRODUCT OFFERINGS
19.8 DEVLAB BIO
19.8.1 BUSINESS OVERVIEW
19.8.2 PRODUCT OFFERINGS
19.9 DISCOVER LABS
19.9.1 BUSINESS OVERVIEW
19.9.2 PRODUCT OFFERINGS
19.10 INTEGRITY LABORATORIES
19.10.1 BUSINESS OVERVIEW
19.10.2 PRODUCT OFFERINGS
19.11 LABORATORY CORPORATION OF AMERICA HOLDINGS
19.11.1 BUSINESS OVERVIEW
19.11.2 PRODUCT OFFERINGS
19.12 MADISON CORE LABORATORIES
19.12.1 BUSINESS OVERVIEW
19.12.2 PRODUCT OFFERINGS
19.13 MAKO MEDICAL LABORATORIES
19.13.1 BUSINESS OVERVIEW
19.13.2 PRODUCT OFFERINGS
19.14 MAYO CLINIC
19.14.1 BUSINESS OVERVIEW
19.14.2 PRODUCT OFFERINGS
19.15 QUEST DIAGNOSTICS
19.15.1 BUSINESS OVERVIEW
19.15.2 PRODUCT OFFERINGS
19.16 RAPIDBIO
19.16.1 BUSINESS OVERVIEW
19.16.2 PRODUCT OFFERINGS
19.17 SHEPARD HEALTH
19.17.1 BUSINESS OVERVIEW
19.17.2 PRODUCT OFFERINGS
19.18 SONIC HEALTHCARE
19.18.1 BUSINESS OVERVIEW
19.18.2 PRODUCT OFFERINGS
19.19 US BIOTEK LABORATORIES
19.19.1 BUSINESS OVERVIEW
19.19.2 PRODUCT OFFERINGS
19.2 UW VIROLOGY LABORATORY
19.20.1 BUSINESS OVERVIEW
19.20.2 PRODUCT OFFERINGS
20 REPORT SUMMARY
20.1 KEY TAKEAWAYS
20.2 STRATEGIC RECOMMENDATIONS
21 QUANTITATIVE SUMMARY
21.1 MARKET BY TYPE
21.2 MARKET BY END-USER
21.3 MARKET BY REGION
22 APPENDIX
22.1 ABBREVIATIONS
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF US MONKEYPOX TESTING MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022
EXHIBIT 3 OVERVIEW OF US MONKEYPOX TESTING MARKET (2022-2025)
EXHIBIT 4 OVERVIEW OF MONKEYPOX DIAGNOSTICS WITHIN TIME FRAMES
EXHIBIT 5 IMPACT OF ONGOING US MONKEYPOX RESEARCH ACTIVITIES
EXHIBIT 6 IMPACT OF GROWING DEVELOPMENT OF RAPID TESTING METHODS
EXHIBIT 7 IMPACT OF RAPIDLY GROWING COMMERCIAL LABORATORY-DEVELOPED MONKEYPOX TESTING
EXHIBIT 8 IMPACT OF INCREASING PRODUCT LAUNCHES
EXHIBIT 9 IMPACT OF ADVANCES IN PCR TECHNOLOGY
EXHIBIT 10 IMPACT OF MONKEYPOX ERADICATION UNLIKELY TO CONTINUE IN US
EXHIBIT 11 IMPACT OF GROWING ACCESS TO VACCINATION AGAINST MONKEYPOX
EXHIBIT 12 IMPACT OF MONKEYPOX CASES IN A SHARP DECLINE
EXHIBIT 13 US MONKEYPOX CASES
EXHIBIT 14 IMPACT OF POTENTIAL RISK OF FALSE MONKEYPOX TEST RESULTS
EXHIBIT 15 US MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 16 US MONKEYPOX TESTING MARKET BY TYPE 2022-2025 (%)
EXHIBIT 17 US MONKEYPOX TESTING MARKET BY END-USER 2022-2025 (%)
EXHIBIT 18 US MONKEYPOX TESTING MARKET BY REGION 2022-2025 (%)
EXHIBIT 19 FIVE FORCES ANALYSIS 2022
EXHIBIT 20 INCREMENTAL GROWTH BY TYPE 2022 & 2025
EXHIBIT 21 US MONKEYPOX TESTING MARKET BY TYPE: INCREMENTAL GROWTH ($ THOUSAND)
EXHIBIT 22 US MONKEYPOX TESTING MARKET BY TYPE: ABSOLUTE GROWTH (%)
EXHIBIT 23 US PCR MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 24 US PCR MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 25 US LATERAL FLOW ASSAY MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 26 US LATERAL FLOW ASSAY MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 27 US OTHER MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 28 US OTHER MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 29 INCREMENTAL GROWTH BY END-USER 2022 & 2025
EXHIBIT 30 US MONKEYPOX TESTING MARKET BY END-USER: INCREMENTAL GROWTH ($ THOUSAND)
EXHIBIT 31 US MONKEYPOX TESTING MARKET BY END-USER: ABSOLUTE GROWTH (%)
EXHIBIT 32 US LABORATORIES MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 33 US LABORATORIES MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 34 US HOSPITALS & CLINICS MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 35 US HOSPITALS & CLINICS MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 36 US INDIVIDUALS MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 37 US OTHER MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 38 INCREMENTAL GROWTH BY REGION 2022 & 2025
EXHIBIT 39 US MONKEYPOX TESTING MARKET BY REGION: INCREMENTAL GROWTH ($ THOUSAND)
EXHIBIT 40 US MONKEYPOX TESTING MARKET BY REGION: ABSOLUTE GROWTH (%)
EXHIBIT 41 SOUTHERN US MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 42 SOUTHERN US MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 43 WESTERN US MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 44 WESTERN US MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 45 NORTHEAST US MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 46 NORTHEAST US MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 47 CENTRAL US MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 CENTRAL US MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 49 US VENDORS OFFERING COMMERCIAL MONKEYPOX TESTING: MARKET DOMINANCE ANALYSIS
EXHIBIT 50 US MONKEYPOX TESTING MARKET: VENDORS OFFERING COMMERCIAL MONKEYPOX TESTING - CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 51 F. HOFFMANN-LA ROCHE : TOTAL REVENUE 2019−2021 ($ BILLION)
EXHIBIT 52 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2019−2021 ($ BILLION)
EXHIBIT 53 THERMO FISHER SCIENTIFIC: TOTAL REVENUE 2019-2021 ($ MILLIONS)
EXHIBIT 54 THERMO FISHER SCIENTIFIC: R&D EXPENDITURE 2020-2021 ($ MILLIONS)
EXHIBIT 55 THERMO FISHER SCIENTIFIC: REVENUE BY BUSINESS SEGMENT 2020-2021 ($ MILLIONS)
EXHIBIT 56 THERMO FISHER SCIENTIFIC: REVENUE BY GEOGRAPHY 2021 ($ MILLIONS)
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2022
TABLE 3 MOLECULAR METHODS FOR NUCLEIC ACID DETECTION
TABLE 4 IMMUNOLOGICAL METHODS FOR ANTIBODY OR ANTIGEN DETECTION
TABLE 5 US MONKEYPOX RESEARCH PRIORITIES
TABLE 6 US MONKEYPOX RESEARCH SUMMARY
TABLE 7 FDA-APPROVED PCR TESTS FOR MONKEYPOX
TABLE 8 COMPANIES OFFERING LATERAL FLOW ASSAY FOR MONKEYPOX TESTING
TABLE 9 US LIST OF LABORATORIES OFFERING NOTIFIED LABORATORY-DEVELOPED MONKEYPOX TESTS
TABLE 10 SOUTHERN US CASE COUNT (2023)
TABLE 11 WESTERN US MONKEYPOX CASE COUNT (2023)
TABLE 12 NORTHEAST US MONKEYPOX CASES COUNT (2023)
TABLE 13 CENTRAL US MONKEYPOX CASES COUNT (2023)
TABLE 14 ABBOTT: MAJOR PRODUCT OFFERINGS
TABLE 15 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 16 QIAGEN: MAJOR PRODUCT OFFERINGS
TABLE 17 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 18 ALPHA DIAGNOSTIC: MAJOR PRODUCT OFFERINGS
TABLE 19 ATLIABIOSYSTEMS: MAJOR PRODUCT OFFERINGS
TABLE 20 APPLIED DNA SCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 21 BIOGX: MAJOR PRODUCT OFFERINGS
TABLE 22 BIONEER: MAJOR PRODUCT OFFERINGS
TABLE 23 CERTEST BIOTEC: MAJOR PRODUCT OFFERINGS
TABLE 24 CO-DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 25 CORDX: MAJOR PRODUCT OFFERINGS
TABLE 26 CREATIVE BIOGENE: MAJOR PRODUCT OFFERINGS
TABLE 27 ELABSCIENCE BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 28 LABNOVATION TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 29 SEEGENE: MAJOR PRODUCT OFFERINGS
TABLE 30 AEGIS SCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 31 ARUP LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 32 APOSTLE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 33 CALIFORNIA DEPARTMENT OF PUBLIC HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 34 CDR COMPANIES: MAJOR PRODUCT OFFERINGS
TABLE 35 CIRRUSDX: MAJOR PRODUCT OFFERINGS
TABLE 36 CLINICAL REFERENCE LABORATORY: MAJOR PRODUCT OFFERINGS
TABLE 37 DEVLAB BIO: MAJOR PRODUCT OFFERINGS
TABLE 38 DISCOVER LABS: MAJOR PRODUCT OFFERINGS
TABLE 39 INTEGRITY LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 40 LABORATORY CORPORATION OF AMERICA HOLDINGS: MAJOR PRODUCT OFFERINGS
TABLE 41 MADISON CORE LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 42 MAKO MEDICAL LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 43 MAYO CLINIC: MAJOR PRODUCT OFFERINGS
TABLE 44 QUEST DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 45 RAPIDBIO: MAJOR PRODUCT OFFERINGS
TABLE 46 SHEPARD HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 47 SONIC HEALTHCARE: MAJOR PRODUCT OFFERINGS
TABLE 48 US BIOTEK LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 49 UW VIROLOGY LABORATORY: MAJOR PRODUCT OFFERINGS
TABLE 50 US MONKEYPOX TESTING MARKET BY TYPE 2022−2025 ($ THOUSAND)
TABLE 51 US MONKEYPOX TESTING MARKET BY TYPE 2022−2025 (%)
TABLE 52 US MONKEYPOX TESTING MARKET BY END-USER 2022−2025 ($ THOUSAND)
TABLE 53 US MONKEYPOX TESTING MARKET BY END-USER 2022−2025 (%)
TABLE 54 US MONKEYPOX TESTING MARKET BY REGION 2022−2025 ($ THOUSAND)
TABLE 55 US MONKEYPOX TESTING MARKET BY REGION 2022−2025 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
